Skip to main content

Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.

Publication ,  Journal Article
Somlo, G; Doroshow, JH; Lev-Ran, A; Ahn, DC; Hwang, L; Raschko, JW; Forman, SJ; Margolin, KA; Morgan, RJ; Leong, LA
Published in: J Clin Oncol
May 1995

PURPOSE: To evaluate the protective effect of low-dose dopamine given as continuous infusion in patients who undergo chemotherapy with the nephrotoxin cisplatin. PATIENTS AND METHODS: Forty-two patients who received high-dose cisplatin-containing chemotherapy entered a prospective, randomized, double-blind, placebo-controlled trial. Twenty-one patients received dopamine, and 21 received placebo. Patients were to receive either infusional dopamine 2 micrograms/kg/min over 48 hours or placebo. Cisplatin 125 mg/m2 was administered 12 hours after initiating dopamine (group D) or placebo (group P). This schedule was repeated twice, 1 week apart. Measurements of serum creatinine, urinary electrolytes and creatinine, urinary excretion of epidermal growth factor (EGF), ototoxicity, parameters of hematopoietic recovery, and duration of hospitalization were analyzed. RESULTS: We observed an increase in serum creatinine level to a peak of 1.9 mg/dL (range, 0.8 to 7.8) in the dopamine group, in comparison to 1.4 mg/dL (range, 0.9 to 3.3) in the placebo group (P = .04). Urinary magnesium excretion increased and EGF excretion decreased in both groups. Urinary sodium, chloride, and potassium excretion were increased in both groups, but more so in the placebo group. Dopamine had no measurable effect on hearing loss, duration of hospitalization, or hematopoietic recovery. CONCLUSION: The use of prophylactic dopamine increased peak serum creatinine levels relative to placebo and failed to prevent cisplatin-induced renal toxicity or ototoxicity. Determination of whether dopamine could reverse chemotherapy-induced renal damage would require a randomized prospective trial.

Duke Scholars

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

May 1995

Volume

13

Issue

5

Start / End Page

1231 / 1237

Location

United States

Related Subject Headings

  • Water-Electrolyte Imbalance
  • Soft Tissue Neoplasms
  • Sarcoma
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Kidney Diseases
  • Humans
  • Hearing Loss
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Somlo, G., Doroshow, J. H., Lev-Ran, A., Ahn, D. C., Hwang, L., Raschko, J. W., … Leong, L. A. (1995). Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial. J Clin Oncol, 13(5), 1231–1237. https://doi.org/10.1200/JCO.1995.13.5.1231
Somlo, G., J. H. Doroshow, A. Lev-Ran, D. C. Ahn, L. Hwang, J. W. Raschko, S. J. Forman, K. A. Margolin, R. J. Morgan, and L. A. Leong. “Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial.J Clin Oncol 13, no. 5 (May 1995): 1231–37. https://doi.org/10.1200/JCO.1995.13.5.1231.
Somlo G, Doroshow JH, Lev-Ran A, Ahn DC, Hwang L, Raschko JW, Forman SJ, Margolin KA, Morgan RJ, Leong LA. Effect of low-dose prophylactic dopamine on high-dose cisplatin-induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion: a randomized, placebo-controlled, double-blind trial. J Clin Oncol. 1995 May;13(5):1231–1237.

Published In

J Clin Oncol

DOI

ISSN

0732-183X

Publication Date

May 1995

Volume

13

Issue

5

Start / End Page

1231 / 1237

Location

United States

Related Subject Headings

  • Water-Electrolyte Imbalance
  • Soft Tissue Neoplasms
  • Sarcoma
  • Prospective Studies
  • Oncology & Carcinogenesis
  • Middle Aged
  • Male
  • Kidney Diseases
  • Humans
  • Hearing Loss